A Comprehensive Review of Mesenchymal Stem Cell Therapy as Adjunctive Treatment for Active Rheumatoid Arthritis
The Problem: When Morning Stiffness Becomes a Life Sentence
You wake up. The familiar ache begins before you open your eyes. Your fingers feel swollen, rigid—like they've been encased in concrete overnight. The morning stiffness that once lasted minutes now stretches into hours. Simple tasks become daily battles: opening a jar, buttoning a shirt, holding a coffee cup without pain.
This is the reality for millions living with rheumatoid arthritis (RA). Beyond the physical discomfort lies a persistent fear—the worry that joint deformities will progress, that disability is inevitable, that your body is slowly betraying you despite your best efforts.
For many patients, conventional treatments bring their own challenges. DMARDs, the cornerstone of RA management, can take 3-6 months to show meaningful effect. Biologics, while effective, carry risks of immunosuppression and significant costs. Side effects from these medications—nausea, fatigue, increased infection risk—can feel like trading one set of problems for another.
The disease typically strikes between ages 30 and 60—prime working and family-building years—adding economic and emotional burdens to physical suffering.
⚖️ But the most important thing to say next is not about stem cells: RA treatment has been transformed, and the transformation is recent enough that a lot of what people "know" about this disease is out of date.
Figures showing that around half of patients became unable to work within a decade come from cohorts treated before modern therapy and before treat-to-target management. That is not the trajectory of a patient diagnosed today and treated early to a target [7][8]. The deformed hands that most people picture when they hear "rheumatoid arthritis" are increasingly a picture of undertreated disease, not of the disease itself.
Everything below about stem cell research should be read against that background — as a possible addition to treatment that works, not as an escape from treatment that doesn't.
Understanding Rheumatoid Arthritis: The Autoimmune Attack
What Is Happening in Your Joints?
Rheumatoid arthritis is a chronic autoimmune disorder characterized by inflammation of the synovial membrane—the tissue lining your joints. Unlike osteoarthritis, which results from mechanical wear and tear, RA is driven by a malfunctioning immune system.
In healthy individuals, the immune system distinguishes between foreign invaders (like bacteria and viruses) and the body's own tissues. In RA patients, this recognition system fails. The immune system mistakenly identifies synovial tissue as a threat and launches a sustained attack.
The Inflammatory Cascade
The pathophysiology of RA involves a complex interplay of immune cells and signaling molecules:
- Autoantibody Production: The immune system generates antibodies (rheumatoid factor and anti-citrullinated protein antibodies) that target the body's own proteins
- Synovial Inflammation: These autoantibodies trigger inflammation in the synovial membrane, causing it to thicken and swell
- Cytokine Storm: Inflammatory cytokines—including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 (IL-1)—amplify the inflammatory response [3]
- Cartilage and Bone Destruction: Over time, the inflamed synovium (called pannus) invades and destroys adjacent cartilage and bone
- Systemic Effects: The inflammation extends beyond joints, potentially affecting the heart, lungs, blood vessels, and eyes
Who Is at Risk?
RA affects approximately 1% of the global population worldwide, with significant gender disparity—women are 2-3 times more likely to develop the condition than men. The disease most commonly manifests between ages 30 and 60, though it can occur at any age.
Genetic factors play a role (certain HLA-DRB1 alleles increase susceptibility), but environmental triggers—including smoking, infections, and hormonal changes—also contribute to disease onset.
Current Treatment Landscape
The Gold Standard: DMARDs
Disease-modifying antirheumatic drugs (DMARDs) remain the foundation of RA treatment. These medications work by suppressing the overall immune response, thereby reducing inflammation and slowing disease progression.
Conventional DMARDs include:
- Methotrexate (the first-line treatment for most patients)
- Sulfasalazine
- Hydroxychloroquine
- Leflunomide
Biologic DMARDs target specific components of the immune system:
- TNF inhibitors (adalimumab, etanercept, infliximab)
- IL-6 inhibitors (tocilizumab)
- T-cell costimulation modulators (abatacept)
- B-cell depleting agents (rituximab)
⚖️ Treat-to-Target: What Modern RA Care Is Actually Aiming At
The single biggest change in RA care is not a drug — it is a strategy. Both major international
guidelines recommend treat-to-target [7][8]: disease activity is measured at regular intervals using a
validated score (most commonly DAS28, sometimes CDAI), and therapy is adjusted until the target —
remission, or at minimum low disease activity — is reached and sustained.
Three things follow from this, and they matter more to your outcome than anything on the rest of this page:
to uncontrolled inflammation does not come back — which is why delay costs more than it appears to at
the time, and why a flare is a permanent loss rather than a bad week.
patients in sustained remission, guidelines support cautious tapering of glucocorticoids first,
then biologics, sometimes conventional DMARDs [7]. **It is a decision made by your rheumatologist on a
measured score after sustained remission — not on how you feel, and not after any treatment you buy.**
⚠️ If anyone suggests a therapy will let you come off your RA drugs, that is the claim to refuse.
- Remission is the goal, and it is achievable for many patients. Not merely "fewer symptoms".
- Early treatment protects joints permanently. ⚠️ RA erosions do not heal. Bone and cartilage lost
- ⚖️ Medication CAN sometimes be reduced — and this is where the honest answer matters most. In
**If you do not know your current DAS28 or whether you are at target, that is the question to bring to
your next rheumatology appointment.**
⚠️ If Your Disease Is Still Active Despite Treatment
This page is aimed at people whose RA is not controlled. **There is a formal guideline for exactly that
situation: EULAR's points to consider for difficult-to-treat RA** [9], covering patients who have failed
multiple therapies. It sets out how to confirm the diagnosis, check adherence, distinguish inflammation
from damage and non-inflammatory pain, and sequence remaining options.
**Before considering an unproven therapy, ask your rheumatologist whether that pathway has been worked
through.** Non-drug management — exercise, rehabilitation and diet — also has its own guideline [10], and is
routinely under-used.
Limitations of Current Approaches
While DMARDs have transformed RA outcomes, significant challenges remain:
For patients with active disease despite conventional therapy, the search for adjunctive treatments becomes urgent.
What the Research Says: Mesenchymal Stem Cell Therapy
The Promise of MSCs
Mesenchymal stem cells (MSCs) are multipotent cells capable of differentiating into various tissue types—including bone, cartilage, and fat cells. However, their therapeutic value in autoimmune conditions like RA stems primarily from their immunomodulatory properties rather than their regenerative potential.
Mechanisms of Action
MSCs help modulate the immune response through multiple mechanisms [3]:
1. T-Cell Modulation
- Inhibit T-cell proliferation and activation
- Promote regulatory T-cell development (Tregs), which help maintain immune tolerance
- Shift T-cell balance from pro-inflammatory (Th1/Th17) to anti-inflammatory (Th2) profiles
2. B-Cell Regulation
- Modulate B-cell function and antibody production
- Reduce autoantibody generation
3. Cytokine Modulation
- Reduce production of inflammatory cytokines (TNF-α, IL-6, IL-1)
- Increase anti-inflammatory cytokines (IL-10, TGF-β)
4. Paracrine Effects
- Secrete extracellular vesicles and exosomes containing bioactive molecules
- Deliver growth factors and microRNAs that promote tissue healing [3]
Clinical Evidence
⚠️ Every mechanism above comes from laboratory and animal work. RA has a large collagen-induced and
serum-transfer arthritis literature in mice, and it is where most of this biology was established. **A
mechanism shown in a mouse is a reason to run a trial, not a result in a person.** What follows is the
human evidence, in full.
The largest study: Wang 2013 — 172 patients
172 patients with active RA and inadequate response to conventional medication received either **DMARDs
plus culture medium (control) or DMARDs plus 40 million UC-MSCs** intravenously [2]·
⚖️ **The most important fact about this trial, and the reason it belongs at the top of this section:
patients in BOTH groups stayed on their DMARDs throughout.* This was never a test of MSCs instead of*
medication. It tested whether adding cells to existing treatment helps. **Nothing in it supports stopping
anything.**
the control group. No serious adverse effects.
needed to sustain them.
not described as randomised or blinded**, which is why 172 patients does not settle the question.
- TNF-α and IL-6 fell after the first treatment (P<0.05); regulatory T cells rose (P<0.05).
- Significant improvement by ACR criteria, DAS28 and the Health Assessment Questionnaire, not seen in
- ⚠️ Benefits were "maintained for 3-6 months without continuous administration." Repeat infusions were
- ⚠️ Design limit: this was an ongoing cohort whose patients were "divided into two groups". **It is
Three-year follow-up: Wang 2019 — 64 patients
64 patients received 20 million UC-MSCs with DMARDs and were followed for 1 and 3 years [3].
improved (all P<0.05).
immunoglobulins were all normal at three years.
before-and-after comparisons overstate benefit.
- ESR, CRP and rheumatoid factor were lower at 1 and 3 years; anti-CCP lower at 3 years; DAS28 and HAQ
- ⚖️ A real long-term safety result: blood counts, liver function, kidney function and
- ⚠️ No control group in this follow-up. RA relapses and remits on its own, so uncontrolled
A different cell source: Ghoryani 2019
A small Iranian trial treated patients with refractory RA using their own bone marrow-derived MSCs
and reported improvement in clinical symptoms [4]. ⚠️ **It is small, uncontrolled, and uses autologous bone
marrow cells — not the umbilical cord cells sold here.** It is included because it is one of only four
human trials in this field, not because it establishes anything on its own.
The randomised placebo-controlled trial: Álvaro-Gracia 2017 — and it did not work
⚠️ This is the trial that tests the therapy most rigorously, and it is the one most often left out of summaries.
53 patients with refractory RA — all had failed at least two biologics — were randomised to three
infusions of allogeneic expanded adipose-derived MSCs at 1, 2 or 4 million/kg, or placebo, in a
multicentre phase Ib/IIa trial with blinded efficacy assessment [5].
month 1: 45%, 20%, 33% versus 29%.
what a null result looks like.
its efficacy endpoints.**
eight were grade 3 (severe) — including a lacunar infarction (a stroke), tendon rupture and
sciatica — and the infarction was classified as a serious adverse event. Any account of this trial
family that reports no serious adverse events is wrong.
- ACR20 response at month 3: 25%, 15% and 17% across the three dose groups, versus 0% for placebo. At
- ⚠️ There was no dose-response — the lowest dose did best and the middle dose worst. That pattern is
- ⚠️ **The authors concluded only that "a trend for clinical efficacy was observed." The trial did not meet
- ⛔ On safety, this is the trial that matters, and it is not clean. There were 141 adverse events;
What the pooled evidence says
A 2023 systematic review and meta-analysis is the best synthesis available: **three randomised trials and
one non-randomised trial, 358 patients in total** [6].
statistically significant. Serious adverse events: 1.10 (95% CI 0.15 to 7.97). ⚠️ The wide intervals
are the honest caveat: with 358 patients, uncommon risks would not be detected.
treatment administration." Durability beyond a year has not been demonstrated.**
extended follow-up."**
- ⚖️ Safety was favourable. Adverse events: risk ratio 2.35 (95% CI 0.58 to 9.58) — not
- DAS28, HAQ, CRP and ESR all decreased, and the authors describe "a trend toward clinical efficacy."
- ⚠️ **"This improvement was not shown in the studies after 12 months of follow-up without continuous
- Their conclusion: efficacy **"must be confirmed through high-quality RCTs, considerable sample size, and
Registered trials — stated accurately
is listed as estimated, the stated completion date was December 2014, and **no results have been
posted.** A registration is a statement of intent and cannot be cited as a finding.
patients**, and it closed in May 2023.
target 200 patients across six autoimmune conditions.
- NCT01547091 (UC-MSCs in RA): ⚠️ a registration only. Registry status is "unknown", enrolment
- NCT03186417 (MSCs in early RA): ⚠️ TERMINATED. It was a phase 1 study that enrolled **10
- NCT06888973 (MSCs in autoimmune disease including RA): currently enrolling by invitation, phase 1/2,
⚠️ The interaction nobody mentions: immunosuppression stacks
MSCs work in RA because they suppress immune activity. That is the whole mechanism.
Your DMARDs and biologics also suppress immune activity — that is their mechanism too. Methotrexate,
TNF inhibitors, rituximab, abatacept, tocilizumab and JAK inhibitors all carry an increased infection
risk, which is why TB screening and vaccination are standard before starting them.
⚠️ **Adding an immunosuppressive cell therapy on top of immunosuppressive drugs means stacking them, and
no trial on this page was designed or powered to measure that combined infection risk.** Delayed
infections after MSC infusion have been reported in other settings.
This does not mean the combination is unsafe — it means it is unmeasured. Discuss it specifically with
your rheumatologist, make sure your vaccinations are current, and treat any fever or infection after
treatment as something to report promptly.
Umbilical cord MSCs
UC-MSCs have higher proliferative capacity than adult-derived MSCs, lower immunogenicity, and are
available without invasive harvesting. ⚖️ **They are also the cell type used in the two largest human RA
studies** [2][3]— unlike most conditions on this site, the cells sold here match the cells studied.
Treatment Options Compared
Key Point: MSC therapy is positioned as complementary to DMARDs, not a replacement. The combination approach appears to offer synergistic benefits.
Is This Right For You?
MSC therapy may be appropriate for patients who:
- Have confirmed rheumatoid arthritis diagnosis
- Experience active disease despite conventional DMARD therapy
- Have inadequate response or intolerance to biologics
- Seek adjunctive treatment to optimize their current regimen
- Are interested in immunomodulatory approaches that address underlying disease mechanisms
Important: MSC therapy is not a cure for RA. It is an adjunctive treatment designed to work alongside conventional medications to improve symptom control and potentially modify disease trajectory.
The Sterling-Certified Approach
Sterling-certified partner clinics have developed a comprehensive treatment protocol designed to maximize the therapeutic potential of regenerative medicine for people with rheumatoid arthritis.
Core Protocol: 7-Day UC-MSC Package
Day 1: Preparation & Inflammation Reduction
- Comprehensive Blood Panel: Baseline assessment of inflammatory markers, immune function and overall health status, and confirmation that you are fit for infusion
⚠️ Exosome and NAD+ infusions are offered as "preparation" before the cells. There is no evidence that either improves the outcome of MSC therapy, and neither was part of any RA trial described on this page. They are bundled into the package price and add materially to the cost. You are entitled to decline them, and to ask what published evidence supports any add-on offered to you.
Day 2+: Core Regenerative Treatment
- UC-MSC infusion: umbilical cord-derived mesenchymal stem cells given intravenously. ⚠️ Confirm your dose in writing before you travel — the protocol is 50 million per session, with up to 100 million total split across two sessions 48-72 hours apart for more severe disease. Quoted figures vary depending on where you read them, so get yours confirmed
- Cell viability released at 95% or above — fresh, not frozen. ⚠️ Viability is a release specification describing the cells that leave the laboratory. It is not a measure of clinical potency, which requires a validated assay that has not been published for this product
- Full Certificate of Analysis documenting your specific cell batch
- ⚖️ For context, the human RA trials used 40 million cells (Wang 2013) and 20 million (Wang 2019) [2][3]. The one trial that tested three ascending doses found no dose-response [5]— more cells is not established as better
- Allogeneic (donor-derived) cells allow for immediate treatment without the 3-week culture period required for autologous harvesting
Days 3-7: Recovery & Optimization
- Follow-up assessments to monitor response
- Additional supportive therapies as clinically indicated
- Protocol optimization based on individual patient response
Premium Add-On Therapies
⚠️ Additional therapies are offered by the partner clinics — NK/NKT cell therapy, plasmapheresis, cord blood plasma and immunokine therapy. None of them has published evidence in rheumatoid arthritis, none appears in the ACR or EULAR treatment guidelines [7][8], and none of them is defined or priced in the clinic's own canonical package document — so ask what each one costs and what it includes, in writing, before agreeing to it.
Two warrant specific comment on an RA page:
- ⚠️ Plasmapheresis is sometimes described as removing autoantibodies. RA does involve autoantibodies (rheumatoid factor, anti-CCP), which makes the claim sound mechanistically apt — but there is no evidence that plasmapheresis improves outcomes in rheumatoid arthritis, and it is not a recommended RA treatment. Sounding plausible is not the same as working.
- ⚠️ NK/NKT cell therapy requires an extended stay abroad for cell culturing. Confirm the length in writing — quoted figures vary between three and four weeks.
If any add-on is recommended to you, ask what published evidence supports it in rheumatoid arthritis specifically, and what it costs. You are entitled to a straight answer and to decline.
What to Expect: Timeline for Inflammation Reduction
Understanding the timeline for response helps set realistic expectations:
Immediate (Days 1-3): Some patients report a sense of improved well-being following the preparatory Day 1 treatments. This may relate to NAD+ energy support and initial exosome activity.
Short-term (Weeks 2-4): The immunomodulatory effects of MSCs begin to manifest. Some patients report reduced morning stiffness and improved joint mobility. However, individual responses vary significantly.
Medium-term (Months 2-6): Clinical studies suggest this is when meaningful clinical benefits typically emerge. Combined with continued DMARD therapy, patients may experience:
- Reduced joint swelling and tenderness
- Decreased inflammatory markers (CRP, ESR)
- Improved functional capacity
Long-term (6+ months): The combination of MSC therapy plus DMARDs has demonstrated persistent clinical benefits in research studies [2]. Regular follow-up with your rheumatologist remains essential for ongoing disease management.
Frequently Asked Questions
Q: Will MSC therapy cure my rheumatoid arthritis?
A: No. There is currently no cure for RA. MSC therapy is an adjunctive treatment designed to work alongside conventional medications to improve symptom control and potentially modify disease trajectory.
Q: Can I stop taking my DMARDs after MSC treatment?
A: No. ⚠️ Every trial on this page gave MSCs in addition to DMARDs — patients in both arms of the largest study stayed on their medication throughout [2][3]. No study has tested MSC therapy as a replacement for DMARDs, and none supports stopping them.
Why this matters more in RA than in most conditions: stopping treatment causes flares, and the bone and cartilage erosions a flare produces are permanent. You do not get that back.
⚖️ There is a real version of this question, and it is worth knowing. Patients who reach sustained remission, confirmed on a measured disease-activity score, may be able to taper therapy under rheumatology supervision — guidelines support cautious reduction, usually glucocorticoids first, then biologics [7][8]. That decision belongs to your rheumatologist and is based on measurement over time. It is not something any purchased treatment earns you, and feeling better is not the same as being in remission.
Q: Is MSC therapy safe?
A: ⚖️ Short-term safety is the best-supported finding in this field. Pooling three randomised trials and one non-randomised trial (358 patients), adverse events were not significantly more common than control (risk ratio 2.35, 95% CI 0.58 to 9.58), nor were serious adverse events (1.10, 95% CI 0.15 to 7.97) [6]. Common effects are mild and transient — fever, infusion reactions.
⚠️ Three limits on that. The confidence intervals are wide, so uncommon risks would not be detected in 358 patients. The randomised placebo-controlled trial did record severe events — eight grade-3 adverse events in six patients, one of them serious (a lacunar infarction) [5]. And the added infection risk of stacking an immunosuppressive therapy on top of immunosuppressive RA drugs has not been measured in any of these trials.
Q: How long do the effects last?
A: ⚠️ Shorter than is often assumed. In the largest study, benefits were "maintained for 3-6 months without continuous administration", with repeat infusions needed to sustain them [2]. The 2023 pooled analysis found that improvement "was not shown in the studies after 12 months of follow-up without continuous treatment administration" [6].
A three-year follow-up study did report sustained improvement in DAS28 and inflammatory markers [3]— ⚠️ but it had no control group, and RA relapses and remits on its own. Plan on the basis that any benefit is likely to require repeat treatment, and budget accordingly.
Q: Will my body reject the umbilical cord MSCs?
A: UC-MSCs have low immunogenicity and are well-tolerated [3]. They are considered "immune privileged" and do not require tissue matching like organ transplants.
Q: What makes your protocol different from other stem cell clinics?
A: Dosing is physician-determined: 50 million UC-MSCs per session, with up to 100 million total split across two sessions (50M + 50M, 48-72 hours apart) for more severe disease. Cells are allogeneic and fresh, with a Certificate of Analysis per batch.
⚠️ The preparatory infusions (exosomes, NAD+) and the optional add-ons are not supported by evidence in rheumatoid arthritis. A protocol being more extensive is not the same as it being more effective. Ask for the full itemised cost and the evidence for each item.
Q: How soon can I receive treatment?
A: Because allogeneic UC-MSCs are used (not autologous cells requiring culture), treatment can begin immediately after consultation and medical clearance.
Q: What should I ask my rheumatologist before doing this?
A: Five questions worth taking to your appointment:
- What is my current DAS28 or CDAI, and am I at target? If you are not at target, guideline-directed adjustment of your existing therapy comes first [7][8].
- Have we worked through the difficult-to-treat RA pathway? There is a formal guideline for patients who have failed multiple therapies [9].
- Am I a candidate for a clinical trial? Trial enrolment gives monitored access to cell therapy, usually at no cost.
- What is my infection risk if I add an immunosuppressive therapy to my current drugs, and are my vaccinations current?
- Would you want to see my results afterwards? Any treatment you have should be reported back into your rheumatology record.
Q: Is this treatment FDA-approved?
A: MSC therapy for RA is considered experimental and is not yet FDA-approved. It falls under the category of regenerative medicine procedures. You should discuss all treatment options with your rheumatologist.